Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Aspen Neuroscience , Inc.
Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in “Cell Stem Cell”
September 18, 2026
Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson’s Disease
July 30, 2026
Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson’s Disease
June 30, 2026
Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary
June 11, 2026